Filariasis in Africa-treatment challenges and prospects

Clinical Microbiology and Infection

Volumn 17, Issue 7, 2011, Pages 977-985

  Hoerauf, A ^a   Pfarr, K ^a   Mand, S ^a   Debrah, A Y ^b,c   Specht, S ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^c KUMASI CENTRE FOR COLLABORATIVE RESEARCH IN TROPICAL MEDICINE   (Ghana)

Author keywords

Albendazole; AWOL; Diethylcarbamazine; DOLF; Filarial diseases; Ivermectin; Treatment and research aspects; Wolbachia

Indexed keywords

ALBENDAZOLE; DIETHYLCARBAMAZINE; INDUCIBLE NITRIC OXIDE SYNTHASE; IVERMECTIN;

AFRICA; BRUGIA MALAYI; DIROFILARIA; DRUG EFFICACY; HUMAN; HYDROCELE; HYPERPOLARIZATION; LOIASIS; LYMPHANGIOGENESIS; LYMPHATIC FILARIASIS; LYMPHEDEMA; MANSONELLA; NONHUMAN; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIMULIUM; SINGLE DRUG DOSE; TREATMENT RESPONSE; WUCHERERIA BANCROFTI;

ENDOBACTERIA; LOA LOA; ONCHOCERCA VOLVULUS; WOLBACHIA; WUCHERERIA BANCROFTI;

EID: 79959961835     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03586.x     Document Type: Review

References (59)

1. World Health Organization. African Programme for onchocerciasis control-report of the sixth meeting of national task forces, October 2009. Wkly Epidemiol Rec 2010; 85: 23-28.
2. World Health Organization. Global Programme to eliminate lymphatic filariasis: progress report on mass drug administration in 2009. Wkly Epidemiol Rec 2010; 85: 365-372.
3. World Health Organization. Onchocerciasis: elimination is feasible. Wkly Epidemiol Rec 2009; 84: 382-384.
4. World Health Organization. Meeting of the international task force for disease eradication-October 2010. Wkly Epidemiol Rec 2011; 86: 53-59.
5. Evans DB, Gelband H, Vlassoff C. Social and economic factors and the control of lymphatic filariasis: a review. Acta Trop 1993; 53: 1-26.
6. Little MP, Breitling LP, Basanez MG, Alley ES, Boatin BA. Association between microfilarial load and excess mortality in onchocerciasis: an epidemiological study. Lancet 2004; 363: 1514-1521.
7. Pion SD, Kamgno J, Demanga N, Boussinesq M. Excess mortality associated with blindness in the onchocerciasis focus of the Mbam Valley, Cameroon. Ann Trop Med Parasitol 2002; 96: 181-189.
8. World Health Organization. Metrics: disability-adjusted life year (DALY). 2011. Available at: (last accessed 8 March 2011).
9. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Ehrlich Sachs S, Sachs JD. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med 2006; 3: e102.
10. Guerrant RL, Walker DH, Weller PF. Tropical infectious diseases: principles, pathogens and practice, 2nd edn. Maryland Heights: Churchill Livingstone, 2010.
11. Anonymous. Report of a scientific working group on serious adverse events following mectizan(r) treatment of onchocerciasis in Loa loa endemic areas. Filaria J. 2004; 2 (suppl 1): S2.
12. Mand S, Debrah AY, Klarmann U et al. The role of ultrasonography in the differentiation of the various types of filaricele due to bancroftian filariasis. Acta Trop 2010. DOI:
13. Bennuru S, Maldarelli G, Kumaraswami V, Klion AD, Nutman TB. Elevated levels of plasma angiogenic factors are associated with human lymphatic filarial infections. Am J Trop Med Hyg 2010; 83: 884-890.
14. Bennuru S, Nutman TB. Lymphangiogenesis and lymphatic remodeling induced by filarial parasites: implications for pathogenesis. PLoS Pathog 2009; 5: e1000688.
15. Debrah AY, Mand S, Marfo-Debrekyei Y et al. Reduction in levels of plasma vascular endothelial growth factor-A and improvement in hydrocele patients by targeting endosymbiotic Wolbachia sp. in Wuchereria bancrofti with doxycycline. Am J Trop Med Hyg 2009; 80: 956-963.
16. Debrah AY, Mand S, Specht S et al. Doxycycline reduces plasma VEGF-C/SVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog 2006; 2: e92.
17. Turner JD, Langley RS, Johnston KL et al. Wolbachia lipoprotein stimulates innate and adaptive immunity through toll-like receptors 2 and 6 to induce disease manifestations of filariasis. J Biol Chem 2009; 284: 22364-22378.
18. Brattig NW, Bazzocchi C, Kirschning CJ et al. The major surface protein of Wolbachia endosymbionts in filarial nematodes elicits responses through TLR2 and TLR4. J Immunol 2004; 173: 437-445.
19. Brattig NW, Büttner DW, Hoerauf A. Neutrophil accumulation around Onchocerca worms and chemotaxis of neutrophils are dependent on Wolbachia endobacteria. Microbes Infect 2001; 3: 439-446.
20. Saint André A, Blackwell NM, Hall LR et al. The role of endosymbiotic Wolbachia bacteria in the pathogenesis of river blindness. Science 2002; 295: 1892-1895.
21. Taylor MJ, Cross HF, Bilo K. Inflammatory responses induced by the filarial nematode Brugia malayi are mediated by lipopolysaccharide-like activity from endosymbiotic Wolbachia bacteria. J Exp Med 2000; 191: 1429-1436.
22. Choi EH, Zimmerman PA, Foster CB et al. Genetic polymorphisms in molecules of innate immunity and susceptibility to infection with Wuchereria bancrofti in South India. Genes Immun 2001; 2: 248-253.
23. Debrah AY, Mand S, Toliat MR et al. Plasma vascular endothelial growth factor-A (VEGF-A) and VEGF-A gene polymorphism are associated with hydrocele development in lymphatic filariasis. Am J Trop Med Hyg 2007; 77: 601-608.
24. Hise AG, Gillette-Ferguson I, Pearlman E. Immunopathogenesis of Onchocerca volvulus keratitis (river blindness): a novel role for TLR4 and endosymbiotic Wolbachia bacteria. J Endotoxin Res 2003; 9: 390-394.
25. Terhell AJ, Houwing-Duistermaat JJ, Ruiterman Y, Haarbrink M, Abadi K, Yazdanbakhsh M. Clustering of Brugia malayi infection in a community in South-Sulawesi, Indonesia. Parasitology 2000; 120 (Pt 1): 23-29.
26. Wahyuni S, Houwing-Duistermaat JJ, Syafruddin, Supali T, Yazdanbakhsh M, Sartono E. Clustering of filarial infection in an age-graded study: genetic, household and environmental influences. Parasitology 2004; 128: 315-321.
27. Hoerauf A, Kruse S, Brattig NW, Heinzmann A, Mueller-Myhsok B, Deichmann KA. The variant Arg110Gln of human IL-13 is associated with an immunologically hyper-reactive form of onchocerciasis (sowda). Microbes Infect 2002; 4: 37-42.
28. Doetze A, Satoguina J, Burchard G et al. Antigen-specific cellular hyporesponsiveness in a chronic human helminth infection is mediated by T(h)3/T(r)1-type cytokines IL-10 and transforming growth factor-beta but not by a T(h)1 to T(h)2 shift. Int Immunol 2000; 12: 623-630.
29. Korten S, Badusche M, Buttner DW, Hoerauf A, Brattig N, Fleischer B. Natural death of adult Onchocerca volvulus and filaricidal effects of doxycycline induce local foxp3+/CD4+ regulatory T cells and granzyme expression. Microbes Infect 2008; 10: 313-324.
30. Satoguina J, Mempel M, Larbi J et al. Antigen-specific T regulatory-1 cells are associated with immunosuppression in a chronic helminth infection (onchocerciasis). Microbes Infect 2002; 4: 1291-1300.
31. Korten S, Hoerauf A, Kaifi JT, Buttner DW. Low levels of transforming growth factor-beta (TGF-beta) and reduced suppression of Th2-mediated inflammation in hyperreactive human onchocerciasis. Parasitology 2010; 138: 35-45.
32. Brattig NW, Schwohl A, Hoerauf A, Buttner DW. Identification of the lipid mediator prostaglandin E2 in tissue immune cells of humans infected with the filaria Onchocerca volvulus. Acta Trop 2009; 112: 231-235.
33. Brattig NW, Tenner-Racz K, Korten S, Hoerauf A, Buttner DW. Immunohistology of ectopic secondary lymph follicles in subcutaneous nodules from patients with hyperreactive onchocerciasis (sowda). Parasitol Res 2010; 107: 657-666.
34. Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 1997; 350: 18-22.
35. Chu BK, Hooper PJ, Bradley MH, McFarland DA, Ottesen EA. The economic benefits resulting from the first 8 years of the global programme to eliminate lymphatic filariasis (2000-2007). PLoS Negl Trop Dis 2010; 4: e708.
36. Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet 2010; 376: 1175-1185.
37. McGarry HF, Plant LD, Taylor MJ. Diethylcarbamazine activity against Brugia malayi microfilariae is dependent on inducible nitric-oxide synthase and the cyclooxygenase pathway. Filaria J 2005; 4.
38. Omura S, Crump A. The life and times of ivermectin-a success story. Nat Rev Microbiol 2004; 2: 984-989.
39. Moreno Y, Nabhan JF, Solomon J, Mackenzie CD, Geary TG. Ivermectin disrupts the function of the excretory-secretory apparatus in microfilariae of Brugia malayi. Proc Natl Acad Sci USA 2010; 107: 20120-20125.
40. Critchley J, Addiss D, Gamble C, Garner P, Gelband H, Ejere H. International Filariasis Review Group. Albendazole for lymphatic filariasis. Cochrane Database Syst Rev 2005; Issue 4: CD003753.
41. Gyapong JO, Kumaraswami V, Biswas G, Ottesen EA. Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opin Pharmacother 2005; 6: 179-200.
42. Addiss D. The 6th meeting of the global alliance to eliminate lymphatic filariasis: a half-time review of lymphatic filariasis elimination and its integration with the control of other neglected tropical diseases. Parasit Vectors 2010; 3.
43. Cheun HI, Lee JS, Cho SH, Kong Y, Kim TS. Elimination of lymphatic filariasis in the Republic of Korea: an epidemiological survey of formerly endemic areas, 2002-2006. Trop Med Int Health 2009; 14: 445-449.
44. Awadzi K, Boakye DA, Edwards G et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 2004; 98: 231-249.
45. Osei-Atweneboana MY, Eng JK, Boakye DA, Gyapong JO, Prichard RK. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet 2007; 369: 2021-2029.
46. Carme B, Boulesteix J, Boutes H, Puruehnce MF. Five cases of encephalitis during treatment of loiasis with diethylcarbamazine. Am J Trop Med Hyg 1991; 44: 684-690.
47. Wanji S, Tendongfor N, Nji T et al. Community-directed delivery of doxycycline for the treatment of onchocerciasis in areas of co-endemicity with loiasis in Cameroon. Parasit Vectors 2009; 2.
48. Cupp EW, Sauerbrey M, Richards F. Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan(r)) monotherapy. Acta Trop 2009; doi:10.1016/j.actatropica.2010.08.009. Dec 11 [Epub ahead of print].
49. Plaisier AP, van Oortmarssen GJ, Habbema JD, Remme J, Alley ES. Onchosim: a model and computer simulation program for the transmission and control of onchocerciasis. Comput Methods Programs Biomed 1990; 31: 43-56.
50. Winnen M, Plaisier AP, Alley ES et al. Can ivermectin mass treatments eliminate onchocerciasis in Africa? Bull World Health Organ 2002; 80: 384-391.
51. Hoerauf A, Mand S, Adjei O, Fleischer B, Büttner D. Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet 2001; 357: 1415-1416.
52. Hoerauf A, Volkmann L, Hamelmann C et al. Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet 2000; 355: 1242-1243.
53. Turner JD, Tendongfor N, Esum M et al. Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulus in an area of Loa loa co-endemicity: a randomized controlled trial. PLoS Negl Trop Dis 2010; 4: e660.
54. Hoerauf A, Specht S, Büttner M et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med Microbiol Immunol 2008; 197: 295-311.
55. Specht S, Hoerauf A, Adjei O, Debrah A, Buttner DW. Newly acquired onchocerca volvulus filariae after doxycycline treatment. Parasitol Res 2009; 106: 23-31.
56. Debrah AY, Mand S, Marfo-Debrekyei Y et al. Macrofilaricidal effect of 4 weeks of treatment with doxycycline on Wuchereria bancrofti. Trop Med Int Health 2007; 12: 1433-1441.
57. Awadzi K. Clinical picture and outcome of serious adverse events in the treatment of onchocerciasis. Filaria J 2003; 2 (suppl 1).
58. Specht S, Mand S, Marfo-Debrekyei Y et al. Efficacy of 2- and 4-week rifampicin treatment on the wolbachia of Onchocerca volvulus. Parasitol Res 2008; 103: 1303-1309.
59. Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion through control of neglected tropical diseases. Lancet 2009; 373: 1570-1575.